Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes

被引:137
作者
Heesom, AE [1 ]
Hibberd, ML [1 ]
Millward, A [1 ]
Demaine, AG [1 ]
机构
[1] UNIV PLYMOUTH,PLYMOUTH POSTGRAD MED SCH,DEPT MED,PLYMOUTH PL4 8AA,DEVON,ENGLAND
关键词
D O I
10.2337/diabetes.46.2.287
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent studies suggest that the gene encoding aldose reductase (ALR2), the enzyme that converts glucose to sorbitol, may confer susceptibility to microvascular disease. DNA from 275 British Caucasian patients with type I diabetes and 102 normal healthy control patients were typed for a (CA)n dinucleotide repeat polymorphic marker in the 5'-region of the ALR2 gene using polymorase chain reaction (PCR). A highly significant decrease in the frequency of the Z+2 allele was found in patients with nephropathy (nephropathy group) compared with those with no complications after a 20-year duration of diabetes (uncomplicated group) (12.7 vs. 38.2%, respectively, chi(2) = 18.6, P < 0.00001); this was accompanied by an increase in the Z-2 allele in the nephropathy group (32.0 vs. 12.7% in the uncomplicated group), The nephropathy group also had a significant decrease in the Z/Z+2 genotype compared with the uncomplicated patients (10.7 vs. 44.7%, chi(2) = 16.0, P < 0.0001) and an increased frequency of the Z/Z-2 genotype. There was no significant association with diabetic retinopathy. These results demonstrate that the ALR2 gene may play a role in susceptibility to diabetic nephropathy; individuals with the Z+2 allele are more than seven times less likely to develop diabetic renal disease than those without this marker. This marker may prove valuable in screening for patients with diabetic nephropathy at diagnosis of diabetes.
引用
收藏
页码:287 / 291
页数:5
相关论文
共 37 条
  • [11] AMINOGUANIDINE, A NOVEL INHIBITOR OF NITRIC-OXIDE FORMATION, PREVENTS DIABETIC VASCULAR DYSFUNCTION
    CORBETT, JA
    TILTON, RG
    CHANG, K
    HASAN, KS
    IDO, Y
    WANG, JL
    SWEETLAND, MA
    LANCASTER, JR
    WILLIAMSON, JR
    MCDANIEL, ML
    [J]. DIABETES, 1992, 41 (04) : 552 - 556
  • [12] *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401
  • [13] DVORNIK D, 1987, ALDOSE REDUCTASE INH, P7
  • [14] CLONING, GENOMIC ORGANIZATION, AND OSMOTIC RESPONSE OF THE ALDOSE REDUCTASE GENE
    FERRARIS, JD
    WILLIAMS, CK
    MARTIN, BM
    BURG, MB
    GARCIAPEREZ, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (22) : 10742 - 10746
  • [15] THE ALDOSE REDUCTASE CONTROVERSY
    FRANK, RN
    [J]. DIABETES, 1994, 43 (02) : 169 - 172
  • [16] GRAHAM A, 1991, HUM GENET, V86, P509
  • [17] GRAHAM A, 1991, J BIOL CHEM, V266, P6872
  • [18] ASSOCIATION OF ERYTHROCYTE ALDOSE REDUCTASE-ACTIVITY WITH DIABETIC COMPLICATIONS IN TYPE-1 DIABETES-MELLITUS
    HAMADA, Y
    KITOH, R
    RASKIN, P
    [J]. DIABETIC MEDICINE, 1993, 10 (01) : 33 - 38
  • [19] CRUCIAL ROLE OF ALDOSE REDUCTASE-ACTIVITY AND PLASMA-GLUCOSE LEVEL IN SORBITOL ACCUMULATION IN ERYTHROCYTES FROM DIABETIC-PATIENTS
    HAMADA, Y
    KITOH, R
    RASKIN, P
    [J]. DIABETES, 1991, 40 (10) : 1233 - 1240
  • [20] T-CELL RECEPTOR CONSTANT BETA-CHAIN POLYMORPHISMS AND SUSCEPTIBILITY TO TYPE-1 DIABETES
    HIBBERD, ML
    MILLWARD, BA
    WONG, FS
    DEMAINE, AG
    [J]. DIABETIC MEDICINE, 1992, 9 (10) : 929 - 933